View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. Comment
February 12, 2020updated 12 Jul 2022 11:57am

Failure of DIAN-TU drug trial for Alzheimer’s disease

By GlobalData Healthcare

Eli Lilly and F. Hoffman-La Roche announced the failure of the clinical trial named DIAN-TU, which was testing two monoclonal antibody (mAb) drugs for Alzheimer’s disease (AD), Roche’s gantenerumab and Eli Lilly’s solanezumab, in patients who have a rare genetic mutation that causes early-onset AD.

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

DIAN-TU was a phase two / three, randomised, double-blind, placebo-controlled study to test solanezumab and gantenerumab in subjects with a rare inherited form of early-onset dementia called autosomal-dominant AD (ADAD). As these individuals show signs of degeneration at a predictable age, researchers hoped to be able to show clinical efficacy in a small study population.

The study was determined not to have achieved its primary endpoint, the DIAN Multivariate Cognitive Endpoint, which is designed to assess cognitive performance in ADAD patients. Eli Lilly stated that it would not pursue the submission of the drug for approval to treat people with dominantly inherited AD.

Data from DIAN-TU presented disappointing results in some earlier studies, but the doses in this study ranged up to four to five times higher and researchers had hoped that would prove more effective, as was seen with Biogen’s aducanumab. However, in the DIAN-TU study, the very small sample size and the late increase of doses affected the results of the trial. Some positive signals are likely to emerge in the full results, which will be presented in April at the Advances in Alzheimer’s and Parkinson’s Therapies (AAT-AD / PD) conference in Vienna.

Key opinion leaders (KOLs) interviewed by GlobalData explained that solanezumab remains under investigation in the Anti-Amyloid Treatment in Asymptomatic Alzheimer’s (A4) study, which is targeting preclinical participants, cognitively normal people with amyloid beta (Aβ) accumulation. This target may be particularly appropriate for treatment with solanezumab.

However, for gantenerumab, they believe that the drug has a lot of similarities with aducanumab. It was tested in two studies in people with early symptomatic AD where it did not seem to be effective for the total study group. However, in a subgroup of people that reached higher plasma concentrations, it seemed to show a clinical signal and also good target engagement. An increased dose of gantenerumab is currently being studied in two trials, GRADUATE 1 and 2, that target early symptomatic AD patients, so mild cognitive impairment and mild AD results are expected in 2022.

Several AD clinical trials have been discontinued due to failure to reverse or even slow the cognitive decline associated with the disease, leading some researchers to question whether they are pursuing the right target. The long list of phase three clinical trial failures has raised doubts about the approach and not all scientists are convinced that Aβ is the primary cause of AD, casting doubts about the potential of these drugs to be successful clinically and commercially.

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena